Tuberculosis Infection Clinical Trial
— New Assay TBOfficial title:
Development of Device Kit for Rapid and Sensitive Diagnostic Method for the Tuberculosis; Using Amine Groups Called HI(Homobifunctional Imidoesters),Negative Charge of the Pathogen and Formed Electrical Bonding to Isolate and Concentrate the Pathogen
Verified date | July 2021 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
It is intended for patients who have been admitted to the outpatient or emergency room or are hospitalized For patients who diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using Xpert TB/RIF, additionally, diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using a new diagnostic method, and check the test results. Check whether the tuberculosis bacteria were actually cultured in the sample in the future, and compare the sensitivity and specificity in each test. Validation in animal model In an animal model (rat) with chronic obstructive pulmonary disease that shows similar characteristics to tuberculosis destructive lung, It will be investigated whether the HI method can be validated by separating and concentrating microbiome for various pathogens including Mycobacterium tuberculosis using HI method. Confirm.
Status | Enrolling by invitation |
Enrollment | 400 |
Est. completion date | December 31, 2023 |
Est. primary completion date | November 17, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 19 Years to 100 Years |
Eligibility | Inclusion Criteria: - Pulmonary TB - Extrapulmonary TB Exclusion Criteria: - under 19 |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center, University of Ulsan College of Medicine | Seoul | Songpa |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1. — View Citation
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95. Review. — View Citation
Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47-55. doi: 10.4046/trd.2015.78.2.47. Epub 2015 Apr 2. Review. — View Citation
Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, Na KI, Cho EH, Shin SS. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis (Seoul). 2012 Jul;73(1):48-55. doi: 10.4046/trd.2012.73.1.48. Epub 2012 Jul 31. — View Citation
Rufai SB, Singh A, Singh J, Kumar P, Sankar MM, Singh S; TB Research Team. Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. J Infect. 2017 Aug;75(2):125-131. doi: 10.1016/j.jinf.2017.04.010. Epub 2017 May 10. — View Citation
Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE; Tuberculous Meningitis International Research Consortium. Tuberculous meningitis. Nat Rev Neurol. 2017 Oct;13(10):581-598. doi: 10.1038/nrneurol.2017.120. Epub 2017 Sep 8. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity and specificity when using Xpert TB/RIF tests with | Comparison of sensitivity and specificity of existing Xpert TB/RIF tests and new diagnostic methods using Homobifunctional Imidoesters (HI) compounds in diagnosing suspected cases of pulmonary tuberculosis and pulmonary tuberculosis
And the sensitivity and specificity of these two test results are evaluated by waiting for the tuberculosis bacillus culture test for 6 weeks and using the final culture-positive patient as a gold standard for tuberculosis diagnosis. |
From date of experiment until the date of first documented progression assessed upto 100 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Completed |
NCT04545164 -
Computer Aided Screening for Tuberculosis in Low Resource Environments
|
N/A | |
Recruiting |
NCT05766267 -
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05756582 -
Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
|
||
Recruiting |
NCT04148053 -
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
|
||
Recruiting |
NCT01689831 -
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
|
Phase 2 | |
Completed |
NCT05945498 -
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
|
Phase 1 | |
Not yet recruiting |
NCT06352970 -
Effects of Tuberculosis Infection on Development and Function of the Placenta
|
||
Recruiting |
NCT04575519 -
Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
|
Phase 2 | |
Recruiting |
NCT05413551 -
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
|
Phase 1 | |
Recruiting |
NCT03941210 -
Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
|
||
Completed |
NCT04494516 -
Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
|
||
Withdrawn |
NCT03265977 -
A Phase II Study of H56:IC31 in Healthy Adolescents
|
Phase 2 | |
Recruiting |
NCT05069688 -
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
|
Phase 1 | |
Suspended |
NCT05330884 -
BCG Revaccination in Children and Adolescents
|
Phase 3 | |
Recruiting |
NCT05342064 -
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
|
N/A | |
Recruiting |
NCT05236452 -
Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection
|
N/A | |
Recruiting |
NCT05443178 -
Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
|
Phase 1 | |
Recruiting |
NCT05122026 -
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
|
Phase 1/Phase 2 | |
Recruiting |
NCT06221488 -
Testing Health Workers At Risk to Advance Our Understanding of TB Infection
|